CurrentUnitedHealthcarePolicy N/A

Maine: Medication alternatives to opioid products (Quick reference guide)

Quick reference guide listing covered non-opioid medication alternatives for pain management and their tier/benefit limits for Maine members and prescribing providers.

Policy Summary

PayerUnitedHealthcare

PolicyMaine: Medication alternatives to opioid products (Quick reference guide)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionRefer to the formulary tier list to select covered non-opioid medication alternatives and note Non-Formulary products that may be excluded or restricted.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7+document chunks containing medication lists

7drug classes listed

Tier 1-4formulary tiers used

Mainejurisdiction

Coverage Criteria

Products identified as Non-Formulary on the Essential Prescription Drug List are listed in this quick reference and may be excluded from coverage or subject to restrictions for Maine members. Examples in the guide include formulations of indomethacin and indocin® suspensions, certain lamotrigine (Lamictal®) and lamotrigine XR preparations, pregabalin (Lyrica) formulations, and gabapentin (Neurontin®) preparations. Providers should assume these non-formulary products are not routinely covered and consider formulary alternatives or prior authorization processes where applicable.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions & Prescribing Notes

Prior Authorization

Formulary tiers & Non‑Formulary notes

Formulary tiers and Non-Formulary status are specified throughout the medication list. Providers should verify tier placement (Tier 1–4) when selecting alternatives to opioid products; several listed products are explicitly marked Non-Formulary on the Essential Prescription Drug List which may affect coverage and member cost-share.

Examples of tiering in the policy: multiple NSAIDs, anticonvulsants, antidepressants, topical analgesics, COX-2 inhibitors, and skeletal muscle relaxants are assigned Tier 1–4.
Specific Non-Formulary notices include Indocin® susp and Indomethacin susp (chunk 1), Sprix nasal spray (chunk 2), certain carbamazepine and lamotrigine formulations and kits (chunks 4 and 6), Lyrica and Neurontin formulations (chunk 6).
Non-Formulary status on the Essential Prescription Drug List may require alternate selection or prior authorization — check member benefit details before prescribing.

Step Therapy

Step therapy

No step therapy protocols or requirements are specified in this document for the analgesic alternatives list. If step therapy applies, it would be documented in a separate utilization management policy or the member’s benefit plan.

Document contains no step-therapy rules for initiation or escalation among listed agents.
Providers should confirm plan-specific step therapy via portal or payer contact if concerned.

Note

Quick reference guide

Quick reference guide: this section serves as an at-a-glance listing of covered medication alternatives to opioid products and their tiering/benefit notes. It does not list required authorization forms, clinical documentation templates, or explicit prior authorization criteria in this document.

Use this guide to identify formulary tier and Non-Formulary flags quickly.
For authorization paperwork or clinical criteria, consult the payer’s prior authorization resources or the member’s benefit plan.

Denial Risk

Denial triggers (not specified)

Denial triggers are not specified in the source document. The policy does not list explicit denial conditions or clinical criteria that would lead to claim or prior authorization denial; absence of such guidance means providers must rely on standard medical necessity rules and payer-specific UM policies.

No denial triggers or refusal reasons are provided in this document.
Providers should document clinical rationale and check payer prior authorization/medical necessity criteria to reduce risk of denial.

Background

This quick reference lists classes of non-opioid medications and specific products with associated formulary tiers to guide alternatives for pain management. Key classes and sample products include: NSAIDs (e.g., Daypro® 600mg tab - Tier 4; diclofenac potassium 50mg tab - Tier 2; ibuprofen 400–800mg tabs - Tier 1; indomethacin 25mg, 50mg cap - Tier 1), Antidepressants (e.g., amitriptyline 10–150mg tab - Tier 1; duloxetine 20/30/60mg cap - Tier 2; venlafaxine ER formulations - Tier 3), and Anticonvulsants (e.g., gabapentin 100–800mg forms - Tier 1; carbamazepine and divalproex products across Tiers 1–4; lamotrigine and lamotrigine XR kits with some formulations listed as Non-Formulary). These tier assignments indicate relative formulary placement and benefit limits that clinicians should consider when selecting non-opioid analgesic alternatives.

Definitions

Tier (1-4) — Formulary tier definitions

Tier 1Lowest cost-sharing preferred formulary tier (examples in this guide: diclofenac sodium DR 25mg–75mg, ibuprofen 400–800mg, indomethacin 25mg/50mg cap, ketorolac tromethamine 10mg tab).

Tier 2Intermediate cost-sharing tier for commonly used agents (examples: diclofenac potassium 50mg, etodolac 200–300mg cap, indomethacin 75mg ER cap).

Tier 3Higher cost-sharing tier for select or extended‑release products (examples: diclofenac sodium ER 100mg, EC‑Naprosyn® 375mg, indomethacin 25mg/5mL susp listed as Tier 3 in this guide).

Tier 4Highest formulary tier or non‑preferred; may include non‑formulary designations on the Essential Prescription Drug List (examples: Daypro® 600mg tab, Feldene® 10/20mg, Indocin® susp listed as Non‑Formulary on the Essential Prescription Drug List).

Not Covered / Exclusions

Not covered (examples): products explicitly flagged as Non-Formulary on the Essential Prescription Drug List within the document include Indocin® 25mg/5mL suspension and certain indomethacin suspensions; Lamictal® (several chewable, starter kit, ODT and XR formulations); Lyrica® (pregabalin) preparations noted as Non-Formulary; and Neurontin® (gabapentin) formulations designated Non-Formulary. These items may be excluded or restricted under the member’s benefit; providers should select formulary-designated alternatives where possible.

OpenPayer